ADC Therapeutics
1D
1W
1M
3M
YTD
1Y
5Y
ALL
Why Robinhood?
Robinhood gives you the tools you need to put your money in motion. You can buy or sell ADCT and other ETFs, options, and stocks.About ADCT
ADC Therapeutics SA is a clinical-stage biotechnology company, which engages in the research and development and commercialization of targeted antibody drug conjugates for patients with hematological malignancies and solid tumors. Its clinical-stage product candidates include loncastuximab tesirine, camidanlumab tesirine, and ADCT-602.
CEOAmeet Mallik
CEOAmeet Mallik
Employees265
Employees265
HeadquartersEpalinges, Vaud
HeadquartersEpalinges, Vaud
Founded2011
Founded2011
Employees265
Employees265
ADCT Key Statistics
Market cap547.83M
Market cap547.83M
Price-Earnings ratio-2.92
Price-Earnings ratio-2.92
Dividend yield—
Dividend yield—
Average volume2.64M
Average volume2.64M
High today—
High today—
Low today—
Low today—
Open price$4.09
Open price$4.09
Volume0.00
Volume0.00
52 Week high$4.80
52 Week high$4.80
52 Week low$1.05
52 Week low$1.05
Stock Snapshot
As of today, ADC Therapeutics(ADCT) shares are valued at $4.09. The company's market cap stands at 547.83M, with a P/E ratio of -2.92.
ADC Therapeutics(ADCT) stock opened on 2025-12-15 at $4.09. The price climbed to — and dipped to —.
ADC Therapeutics(ADCT) shares are trading with a volume of 0, against a daily average of 2.64M.
During the past year, ADC Therapeutics(ADCT) stock moved between $1.05 at its lowest and $4.80 at its peak.
During the past year, ADC Therapeutics(ADCT) stock moved between $1.05 at its lowest and $4.80 at its peak.
Analyst ratings
100%
of 6 ratingsBuy
100%
Hold
0%
Sell
0%
People also own
Based on the portfolios of people who own ADCT. This list is generated using Robinhood data, and it’s not a recommendation.